Sanofi supplies injectable polio vaccine to government
Sanofi Pasteur and its affiliate Shantha Biotechnics are in the process of supplying their injectable polio vaccines, through UNICEF, to the Indian Government for its universal immunisation progra... First doses of Injectable Polio Vaccine ShanIPV soon available for Indian infants
This new polio vaccine is manufactured by Shantha in Hyderabad, India Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first shipment of ShanIPV, a brand new injectable, inactivated polio vaccine (IPV) manufactured by its affiliate Shantha Biotechnics, in Hyderabad, India, will occur in a couple of days. These first vaccine doses will [] Lazard Works With Sanofi on $12.7-Billion Deal: Report
Investment bank Lazard is working with Sanofi's management to prepare a sale or listing of its Merial animal health unit, aiming to land the leading advisory job for the deal, which could value the bu... Sanofi sells its Andheri building in Mumbai for Rs 111 cr
Drug firm Sanofi India has sold its commercial property, land along with a building known as Aventis House in Mumbai, for Rs 111 crore.The transaction has been completed on November 20,... Sale of building owned by the Company in Andheri, Mumbai
With reference to the earlier letter dated July 21, 2015 wherein the Company had informed that the Board of Directors of the Company had approved of the Company selling its commercial property, being land admeasuring 5493.1 sq. mts. bearing Survey No. 54-A Hissa No. 2 and C.T.S. No. 18 of Village Chakala, along with the building known as 'Aventis House' standing thereon, situated at Sir Mathuradas Vasanji Road, Andheri (East) Mumbai - 400 093, for a consideration of Rs.1110 million.... Sanofi and RSSDIs Mega Walkathon triggers zest for diabetes control in Lucknow City
Sanofi India Ltd has submitted to BSE a copy of Press Release dated November 01, 2015 titled "Sanofi and RSSDIs Mega Walkathon triggers zest for diabetes control in Lucknow City".
Sanofi stops developing Glenmark drug for multiple sclerosis
Sanofi licensed vatelizumab in 2011 in a deal worth over $600 million, marking Glenmarks first licensing deal for an original product Clarifies on News Item
With reference to news reported on CNBC TV18 on October 29, 2015 - "Setback For Glenmark: 'Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule'.", Sanofi India Ltd has submitted to BSE a copy of Clarification is enclosed. Clarification sought from Sanofi India Ltd
The Exchange has sought clarification from Sanofi India Ltd with reference to news reported on CNBC TV18 on October 29, 2015 - "Setback For Glenmark: 'Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule'."The reply is awaited. Sanofi India Q3 net rises 17% to Rs 72.5 cr
Drug firm Sanofi India today reported 16.93 per cent rise in its standalone net profit to Rs 72.5 crore for the third quarter ended September 30, 2015. The company had posted a net profit of Rs 62...